Results 141 to 150 of about 22,516 (228)

Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study. [PDF]

Jpn J Clin Oncol
Tsuru I, Taguchi S, Tanaka R, Kawai T, Kaneko T, Nakamura Y, Miyauchi Y, Hoshina H, Obinata D, Koshiba M, Shiozaki M, Takahashi J, Kano M, Naito A, Suda S, Noda M, Sugiyama N, Tanaka T, Uemura Y, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada Y, Sato Y, Yamada Y, Nishimatsu H, Murata T, Takahashi S, Takada T, Akiyama Y, Takahashi S, Fujimura T, Fukuhara H, Nakagawa T, Kume H.   +35 more
europepmc   +1 more source

Androgen receptor signaling organizes ferroptosis escape in castration-resistant prostate cancer: a threshold-based model for therapeutic timing. [PDF]

Front Oncol
Wang C, Lv J, Wu J, Wang S, Song S.
europepmc   +1 more source

Development and Characterization of β-Cyclodextrin Inclusion Complexes With Enzalutamide for Easing Administration and Efficacy of the Drug in CRPC

Prostate cancer (PC) is prevalent among men in the US, often leading to castration-resistant prostate cancer (CRPC) with therapy. This is marked by androgen receptor (AR) overexpression, resistance, mutations, and splice variants.
Kolli, Meghana
core  

Prognostic Stratification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line Androgen Receptor Pathway Inhibitor-Based Combination Therapy. [PDF]

Int J Urol
Miyajima K, Yanagisawa T, Fukuokaya W, Sakakibara R, Uchida N, Miszczyk M, Inoue S, Matsukawa A, Urabe F, Mori K, Fujita N, Narita S, Hatakeyama S, Habuchi T, Shariat SF, Kimura T, JHA Collaborative Group.   +16 more
europepmc   +1 more source

A Platform-Independent Binary Gene-Pair Signature Derived from CRPC-Enriched Single-Cell Transcriptomics for Predicting Recurrence-Free Survival in Prostate Cancer. [PDF]

Cancer Manag Res
He Y, Li B, Tan Z, Jiang K, Ju W, Yu W, Zhang M, Liang C.   +7 more
europepmc   +1 more source

CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor. [PDF]

Theranostics
Li J, Sun J, Tan W, Li G, Xiao W, Wu J, Yang W, Chen C, Li Y, Liu J, Liu Y, Liu D, Chen XH, Zhu R, Huang R, Yan J.   +15 more
europepmc   +1 more source

Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors. [PDF]

Pharmacoepidemiol Drug Saf
Asiri IM, Chen RC, Master V, Mi L, James SE, Moore C, Bryce AH, Tilburt JC, Riaz IB, Naqvi SAA, Afzal U, Beach SRH, Cobran EK.   +12 more
europepmc   +1 more source

Correction in CRPC CUA Guideline

Canadian Urological Association Journal, 2015
openaire   +2 more sources

Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Redman JM, Madan RA, Donahue RN, Toney NJ, Karzai F, Strauss J, Palena C, Horn LA, Del Rivero J, Marté JL, Cordes L, Lynch MT, Meyer TJ, Cam M, Soon-Shiong P, Schlom J, Gulley JL.   +16 more
europepmc   +1 more source

CUA-CUOG CRPC Guidelines: A useful compendium [PDF]

Canadian Urological Association Journal, 2015
openaire   +2 more sources